BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,919,982 | -20.3% | 28,206 | -4.5% | 0.01% | -14.3% |
| Q2 2023 | $2,410,044 | +9.5% | 29,524 | -0.5% | 0.01% | 0.0% |
| Q1 2023 | $2,200,995 | +25.0% | 29,667 | +39.6% | 0.01% | +16.7% |
| Q4 2022 | $1,760,951 | +16.2% | 21,247 | +298.6% | 0.01% | 0.0% |
| Q3 2022 | $1,515,000 | -26.6% | 5,330 | -10.4% | 0.01% | -14.3% |
| Q2 2022 | $2,063,000 | -42.6% | 5,947 | -28.4% | 0.01% | -12.5% |
| Q1 2022 | $3,596,000 | -18.6% | 8,304 | -2.7% | 0.01% | -11.1% |
| Q4 2021 | $4,416,000 | +39.2% | 8,535 | +30.3% | 0.01% | 0.0% |
| Q3 2021 | $3,173,000 | +62.3% | 6,549 | +50.8% | 0.01% | +50.0% |
| Q2 2021 | $1,955,000 | +37.9% | 4,342 | +16.9% | 0.01% | +50.0% |
| Q1 2021 | $1,418,000 | +20.2% | 3,714 | -0.1% | 0.00% | 0.0% |
| Q4 2020 | $1,180,000 | -49.7% | 3,717 | -60.8% | 0.00% | -63.6% |
| Q3 2020 | $2,348,000 | -3.9% | 9,478 | +2.5% | 0.01% | -15.4% |
| Q2 2020 | $2,443,000 | +75.4% | 9,251 | +25.9% | 0.01% | +30.0% |
| Q1 2020 | $1,393,000 | -48.7% | 7,348 | -40.7% | 0.01% | -23.1% |
| Q4 2019 | $2,718,000 | -1.2% | 12,382 | -11.9% | 0.01% | -13.3% |
| Q3 2019 | $2,750,000 | -11.9% | 14,053 | -6.2% | 0.02% | -21.1% |
| Q2 2019 | $3,123,000 | -9.9% | 14,980 | -14.2% | 0.02% | -9.5% |
| Q1 2019 | $3,468,000 | +46.0% | 17,466 | +6.4% | 0.02% | +23.5% |
| Q4 2018 | $2,376,000 | -41.3% | 16,416 | -17.2% | 0.02% | -37.0% |
| Q3 2018 | $4,048,000 | +37.6% | 19,834 | -0.3% | 0.03% | +35.0% |
| Q2 2018 | $2,942,000 | -9.2% | 19,885 | -7.3% | 0.02% | -4.8% |
| Q1 2018 | $3,240,000 | +2.4% | 21,451 | -12.2% | 0.02% | -4.5% |
| Q4 2017 | $3,165,000 | +7.8% | 24,428 | +0.5% | 0.02% | -18.5% |
| Q3 2017 | $2,937,000 | +11.0% | 24,297 | +7.9% | 0.03% | +3.8% |
| Q2 2017 | $2,647,000 | +9.4% | 22,527 | -5.3% | 0.03% | +4.0% |
| Q1 2017 | $2,419,000 | -18.2% | 23,798 | -17.3% | 0.02% | -24.2% |
| Q4 2016 | $2,958,000 | -1.6% | 28,767 | +4.8% | 0.03% | -21.4% |
| Q3 2016 | $3,005,000 | -16.8% | 27,446 | -14.3% | 0.04% | -10.6% |
| Q2 2016 | $3,610,000 | +19.9% | 32,015 | +0.5% | 0.05% | +14.6% |
| Q1 2016 | $3,012,000 | -3.6% | 31,870 | -8.2% | 0.04% | +7.9% |
| Q4 2015 | $3,126,000 | +3.4% | 34,728 | +6.2% | 0.04% | -9.5% |
| Q3 2015 | $3,024,000 | -15.6% | 32,707 | -10.1% | 0.04% | -16.0% |
| Q2 2015 | $3,583,000 | -3.0% | 36,386 | -1.2% | 0.05% | +13.6% |
| Q1 2015 | $3,694,000 | +23.7% | 36,834 | +14.0% | 0.04% | +25.7% |
| Q4 2014 | $2,986,000 | – | 32,319 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |